Cramer's 'Mad Money' Recap: Next Week's Game Plan

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- Be careful, it's no longer easy to make money in this market, Jim Cramer warned "Mad Money" viewers Friday as he laid out his game plan for next week's trading.

Cramer said the market will be awaiting the result of the Federal Reserve meeting that begins Tuesday and ends on Wednesday. The last time the Fed spoke, it was a wake-up call to the markets, he said, and he hopes this time the markets are greeted with more tepid comments. If not, be prepared for more ugliness.

Beyond the Fed on Wednesday, Cramer said he'll also be watching the Empire State Fed survey on Monday, where he expects to see numbers that show the economy can't support interest rates that are as high as they are today. The U.S. is still doing better than the rest of the world, he said, but rates have run too far too fast.

On Wednesday, Cramer will also be listening for FedEx ( FDX) and Micron Technologies ( MU). FedEx will either be praised for great results or obliterated for any signs of global weakness. Micron will offer a read on the state of technology, as just about everything electronic now uses the company's memory chips.

Thursday brings earnings from Kroger ( KR), the grocery chain that's knocking it out of the park with private label products, and Pier 1 Imports ( PIR). Cramer said that he still prefers Whole Foods Markets ( WFM) over Kroger, but expects Pier 1 to do well after Restoration Hardware ( RH) saw huge gains in same-store sales.

Finally, on Friday it's Darden Restaurants ( DRI) and CarMax ( KMX) reporting. Cramer said he wants to hear if consumers are cutting back on eating out and if they're still hot for all things auto.

Profitable Covidian

Breaking up is not only easy to do, it's profitable too, Cramer reminded viewers, as he followed up on a corporate spinoff that's taking place soon. He said shares of Covidian ( COV) are already up 57% since he first got behind the company in late-2011, but now that the spin off of its pharmaceutical business, Mallinckrodt, is at hand, there's still a lot more value to be had.

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback